Isis, Lilly Antisense Drug Moves into Phase I Testing

Isis Pharmaceuticals said this week that the first antisense drug to come from the company’s collaboration with Eli Lilly has moved into phase I testing.

The drug, called LY2181308, targets survivin, a molecule that supports the survival of cells that would normally die through programmed cell death or apoptosis, said Isis. Survivin helps in the abnormal growth of cancer cells, and is found in many types of tumors, the company added.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.